G

    Galectin Therapeutics Inc (GALT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.95
    -0.07 (-1.74%)

    Market Cap: $405.42M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    +1.92%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.10-100.0%
    60d ago$-0.10-100.0%
    30d ago$-0.10-100.0%
    7d ago$-0.10-100.0%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.10
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.05---
    Jun 26
    		$-0.14$-0.09-55.56%Miss-16.7%
    Mar 26
    		$-0.08$-0.06-33.33%Miss+46.7%
    Dec 25
    		$-0.08$-0.10+20.00%Beat+57.9%
    Sep 25
    		$-0.13$-0.11-18.18%Miss+27.8%
    Jun 25
    		$-0.12$-0.16+25.00%Beat+40.0%
    Mar 25
    		$-0.15$-0.11-36.36%Miss+21.1%
    Dec 24
    		$-0.19$-0.16-18.75%Miss-18.8%
    Sep 24
    		$-0.18$-0.20+10.00%Beat+25.0%
    Jun 24
    		$-0.20$-0.16-25.00%Miss-33.3%
    Mar 24
    		$-0.19$-0.16-18.75%Miss+0.0%
    Dec 23
    		$-0.16$-0.16+0.00%Beat+11.1%
    Sep 23
    		$-0.24$-0.16-50.00%Miss-71.4%
    Jun 23
    		$-0.15$-0.21+28.57%Beat+6.3%
    Mar 23
    		$-0.19$-0.21+9.52%Beat-11.8%
    Dec 22
    		$-0.18$-0.17-5.88%Miss-50.0%
    Sep 22
    		$-0.14$-0.20+30.00%Beat+0.0%
    Jun 22
    		$-0.16$-0.19+15.79%Beat-6.7%
    Mar 22
    		$-0.17$-0.14-21.43%Miss-54.5%
    Dec 21
    		$-0.12$-0.19+36.84%Beat+7.7%
    Sep 21
    		$-0.14$-0.18+22.22%Beat-40.0%
    Jun 21
    		$-0.15$-0.18+16.67%Beat-36.4%
    Mar 21
    		$-0.11$-0.17+35.29%Beat-83.3%
    Dec 20
    		$-0.13$-0.16+18.75%Beat-8.3%
    Sep 20
    		$-0.10$-0.14+28.57%Beat-100.0%
    Jun 20
    		$-0.11$-0.07-57.14%Miss-83.3%
    Mar 20
    		$-0.06$-0.09+33.33%Beat+70.0%
    Dec 19
    		$-0.12$-0.06-100.00%Miss-50.0%
    Sep 19
    		$-0.05$-0.10+50.00%Beat+28.6%
    Jun 19
    		$-0.06$-0.12+50.00%Beat+45.5%
    Mar 19
    		$-0.20$-0.14-42.86%Miss-66.7%
    Dec 18
    		$-0.08$-0.08+0.00%Beat-14.3%
    Sep 18
    		$-0.07$-0.09+22.22%Beat+46.2%
    Jun 18
    		$-0.11$-0.11+0.00%Beat+21.4%
    Mar 18
    		$-0.12$-0.13+7.69%Beat+20.0%
    Dec 17
    		$-0.07$-0.11+36.36%Beat+41.7%
    Sep 17
    		$-0.13$-0.15+13.33%Beat+31.6%
    Jun 17
    		$-0.14$-0.15+6.67%Beat-
    Mar 17
    		$-0.15$-0.15+0.00%Beat-
    Dec 16
    		$-0.12$-0.17+29.41%Beat-
    Sep 16
    		$-0.19$-0.22+13.64%Beat-

    Key Metrics

    Valuation
    P/E Ratio-9.19EV/EBITDA-4.04x
    Price/FCF-16.38xFCF Yield-6.11%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-3728.00%ROIC15.14%
    Financial Health
    Debt/Equity-0.24xInterest Coverage-2.61x
    Current Ratio0.10xQuick Ratio0.10x
    Trading Statistics
    Beta0.35Avg Volume344.24K
    52-Week High$7.1352-Week Low$2.03

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.86
    SMA 20$3.56
    SMA 50$3.83
    SMA 200$3.47
    EMA 10$3.87
    EMA 20$3.73
    EMA 50$3.57
    EMA 200$3.34

    MACD

    Line: 0.14Signal: 0.06Hist: 0.08

    ADX

    ADX: 23.2+DI: 29.6-DI: 15.0

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down24.0
    PSAR$3.74

    Bollinger Bands

    Upper Band$4.30
    Lower Band$2.82
    %B Position4170%(Upper)
    Band Width0.76

    RSI (14-Day)

    Neutral
    57.6

    Momentum Oscillators

    Stoch %K70.2
    Stoch %D79.0
    Williams %R-37.6
    ROC (10d)12.5%
    Momentum0.44
    CCI (20d)89.8
    MFI (14d)64.3

    Volatility Measures

    ATR (14d)$0.30(7.7%)
    StdDev (20d)0.37
    Hist Vol72.8%(High)

    Volume Flow

    VWAP$3.97
    OBV20.3M
    AD Line4.1M
    CMF (20d)0.208

    Volume Metrics

    Avg Vol (20d)346.6K
    Vol Ratio0.7x
    VWMA (20d)$3.48

    Pivot Points

    R3$4.41
    R2$4.31
    R1$4.16
    Pivot Point$4.06
    S1$3.91
    S2$3.81
    S3$3.66

    Advanced Oscillators

    TSI12.29
    Ultimate Osc52.2
    KST35.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$36,000$0$0$0$80,000$0
    Cost of Revenue$0$0$-12,000$0$0$0$10,000$0$0$0$9,000$0
    Gross Profit$0$0$12,000$0$0$0$-10,000$0$0$0$-9,000$0
    Operating Expenses$3.98M$4.08M$3.37M$4.20M$4.63M$7.90M$12.43M$9.07M$11.29M$9.65M$9.56M$9.17M
    R&D$2.13M$2.23M$1.93M$2.61M$3.26M$6.49M$11.11M$7.59M$9.81M$8.05M$8.23M$7.73M
    SG&A$1.85M$1.85M$1.43M$1.59M$1.36M$1.41M$1.32M$1.47M$1.48M$1.59M$1.33M$1.43M
    Operating Income$-3,982,000$-4,077,000$-3,365,000$-4,198,000$-4,625,000$-7,897,000$-12,428,000$-9,066,000$-11,291,000$-9,648,000$-9,561,000$-9,166,000
    Interest Income$28,000$36,000$26,000$39,000$26,000$35,000$85,000$93,000$80,000$80,000$74,000$62,000
    Interest Expense$2.00M$1.99M$1.94M$1.82M$1.83M$1.74M$1.73M$1.49M$1.27M$1.05M$847,000$835,000
    Income Before Tax$-9,113,000$-5,046,000$-5,500,000$-8,184,000$-7,521,000$-9,631,000$-11,967,000$-11,220,000$-12,371,000$-11,489,000$-9,997,000$-10,428,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,113,000$-5,046,000$-5,500,000$-8,184,000$-7,521,000$-9,631,000$-11,967,000$-11,220,000$-12,371,000$-11,489,000$-9,997,000$-10,428,000
    EBITDA$-7,133,000$-3,082,000$-3,546,000$-6,403,000$-5,719,000$-7,912,000$-10,317,000$-9,810,000$-11,182,000$-10,517,000$-9,215,000$-9,647,000
    EBIT$-7,137,000$-3,094,000$-3,587,000$-6,403,000$-5,721,000$-7,922,000$-10,327,000$-9,819,000$-11,182,000$-10,517,000$-9,224,000$-9,655,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GALT

    News

    Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

    Galectin Therapeutics announced its financial results for the quarter ended June 30, 2026, alongside a business update. Key highlights include an agreement with the FDA on the Phase 3 trial design for belapectin in MASH cirrhosis and portal hypertension, significant capital structure enhancement through the conversion of $105.8 million in debt to common stock by its chairman, and positive data presentations and publications from its NAVIGATE trial. The company anticipates submitting its registrational Phase 3 protocol in Q3 2026 and has sufficient cash to fund operations through June 2027.

    Yahoo! Finance Canada•8/15/26•
    Bullish

    H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11

    H.C. Wainwright has reiterated its Buy rating for Galectin Therapeutics (GALT.US), maintaining a target price of $11. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.

    Moomoo•8/15/26•
    Bullish

    Galectin Therapeutics Releases Q2 2026 Financial Results

    Galectin Therapeutics Inc. (GALT) reported a wider net loss of $0.14 per share, or $9.1 million, for Q2 2026, an increase from $0.12 per share in the prior year. This reflects the company's continued investment in developing new drugs for fibrotic disease and cancer therapies. Despite the widening loss, Wall Street analysts maintain a positive outlook with 4 buy ratings and 1 hold rating, acknowledging the significant capital required for clinical-stage drug development.

    AlphaStreet•8/14/26•
    Somewhat-Bearish

    Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol

    Galectin Therapeutics reported a Q2 2026 net loss of $9.2 million and held $13.3 million in cash. The company plans to submit a registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis in Q3 2026, having aligned with the FDA on key trial elements. Additionally, Chairman Richard Uihlein converted approximately $105.8 million of debt into common stock, significantly strengthening the balance sheet.

    TradingView•8/14/26•
    Somewhat-Bullish

    Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

    Galectin Therapeutics announced its financial results for the quarter ended June 30, 2026, alongside a business update. Key highlights include reaching an agreement with the FDA on the Phase 3 trial design for belapectin in MASH cirrhosis, and the conversion of approximately $105.8 million in debt by its Chairman into common stock, significantly strengthening the company's balance sheet. The company anticipates submitting the registrational Phase 3 protocol in the third quarter of 2026.

    Yahoo Finance Singapore•8/14/26•
    Bullish

    Frequently Asked Questions About GALT

    Does GALT pay dividends?
    Galectin Therapeutics Inc (GALT) does not currently pay a regular dividend.
    What is GALT's market cap?
    Galectin Therapeutics Inc (GALT) has a market capitalization of $405.42M with a current stock price of $3.95.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In